Introduction
Marijuana is the most commonly used illicit drug substance in the United States. 1 The Food and Drug Administration (FDA)
currently classifies marijuana as a Schedule I drug under the Controlled Substances Act, declaring it to have no currently accepted medical use and a high potential for abuse. 2 The term "medical marijuana" has been coined to describe the use of the whole, unprocessed marijuana plant or its extracts 3, 4 The use of medical marijuana has gained significant momentum with the recent legalization of the product in many states. As of March 2016, 23 states and Washington, DC have legalized and approved the use of medical marijuana. In general, these state laws allow for the consumption of medical marijuana under the recommendation of a licensed medical professional and will allow patients to present a legal defense against marijuana possession charges if a medical need for the drug has been properly documented. Most states require that patients and physicians have an established relationship prior to the recommendation of medical marijuana use, and maintain a formal registry of its users. States require patients to register for an identification card and will permit caregivers to obtain other investigators have found that smoked and vaporized cannabis was associated with a reduction in significant pain from HIV-associated sensory neuropathy and central neuropathic pain and HIV/AIDS associated cachexia. 4, [8] [9] [10] [11] [12] Over the past 30 years, substantial research in human and animal models has shown that prolonged use of marijuana may lead to physical dependence and a withdrawal syndrome upon discontinuation. Several mechanisms are thought to play a part in the drug reward system, and the resulting cannabis abuse or dependence. There are two types of cannabinoid receptors, cannabinoid 1 (CB 1 ) and cannabinoid 2 (CB 2 ). The CB 1 receptors are expressed in the central nervous system and are found mainly in the brain, kidney, liver, and lungs. 13, 14 The CB 2 receptors are most commonly associated with the immune system. In the brain, CB 1 receptors are most abundant in the cerebellum, basal ganglia, and hippocampus. 14 These locations explain many of the negative effects seen on short-term memory, impaired motor skills, and delayed reaction time when cannabinoids are inhaled and ingested. 15, 16 Research shows that CB 1 receptors act as modulators of GABA release in the hippocampus. 17 The CB 1 receptors are also found on glutamate and GABA neuron axon terminals in the hippocampus and decrease the excitability of neurons. There they control the release of neurotransmitters, and it is thought that this is the primary means that cannabinoids inhibit hippocampal neuronal activity and disrupt memory. Activation of the CB 1 receptor affects the central nervous system in ways similar to those of other reward-enhancing drugs such as alcohol, cocaine, and opioids, and is the accepted mechanism for the addictive properties of cannabinoids.
14, [16] [17] [18] Chronic use of illicit and medicinal marijuana may lead to dependence or addiction. Chronic cannabis users develop tolerance to its effects and report being unable to control their use despite negative consequences. 15 Mental health surveys indicated that cannabis dependence is the most common type of drug dependence after alcohol and tobacco. 16 According to the National Institute on Drug Abuse, marijuana overstimulation of the endocannabinoid system can lead to addiction. Approximately 9 percent of marijuana users will become dependent (frequency of use undefined), and 20 to 50% of daily users will become dependent. 3, 16 Cannabis use disorder, defined as increased tolerance, compulsive use, craving, inability to cut down or control cannabis use, and withdrawal, is triggered by chronic marijuana use. 19 Patients with cannabis use disorders seeking discontinuation often report withdrawal symptoms including major mood changes, anxiety, appetite disturbance, depression, and personality changes. 1, 15 Compton et al evaluated the prevalence of marijuana use disorders and found that marijuana abuse or dependence increased by 18% from 30.2% in 1991-1992 to 35.6% in [2001] [2002] . Current literature suggests that factors such as increased potency of marijuana may contribute to increased physical dependence. 1, 15 States with legalized medicinal marijuana currently have no statutes governing the potency of marijuana products, and there is no normalization of product potency. As such, patients using medical marijuana may be at greater risk for addiction potential with chronic use.
There is a perception that increased legalization may be associated with increased use because the public may consider that marijuana's adverse effect profile is benign. Cerdá et al evaluated the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence according to the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). The investigators found that residents of states who had marijuana legalization laws had higher odds of marijuana use (OR, 1.92; 95% CI, 1.49 -2.47) and marijuana abuse/dependence (OR, 1.81; 95% CI, 1.22 -2.67) than residents of states without legalization status. However, abuse/dependence was not more prevalent among users in these states (OR, 1.03; 95% CI, 0.67 -1.60). As a result, higher rates of abuse/dependence in the states with legalized
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3 marijuana may be due to the higher rates of use in these states.
20,21
Although an increasing number of states have passed laws and others have laws on the horizon, the long-term consequences of medical marijuana have not been fully elucidated. 5 Recent changes in medical marijuana policies suggest greater acceptance of marijuana use in our society, and may cause users to feel it is a benign drug with a limited adverse side effect profile or potential for addiction.
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The upsurge of dispensaries and patients growing their own medicinal supply of marijuana makes it imperative that the public and healthcare workers understand the possible therapeutic benefits of marijuana along with the known adverse health effects linked to marijuana. 3 In addition, the role of pharmacists in educating patients who may be taking medical marijuana needs to be identified. The purpose of this review is to provide an overview of the addiction potential; adverse effects (e.g., cardiovascular, immune dysfunction, respiratory system, mental health disorders); drug interactions; effects of accidental exposure; crime statistics; and pharmacist's considerations for the use of medical marijuana.
Methods
A PubMed search was conducted from 1966 to March 2016 to identify articles in which the safety of inhaled medical marijuana was assessed. Key MeSH search terms included medical marijuana with a subheading for adverse effect. Only articles in adult patients were included. In addition, medical marijuana or cannabis plus one of the following search terms were searched: drug interactions, herb-drug interactions, drug-related side effects and adverse drug reactions, substance-related disorders, addiction, and abuse. A freetext search was also conducted to identify articles not included in the MeSH term search. A bibliographic search was also conducted. An Internet search was conducted to locate the most up-to-date information on the laws concerning medical marijuana. Articles were included if they addressed adverse effects of medical marijuana for the treatment of a condition. Meta-analyses, randomized controlled clinical trials, and case reports were included in the review if the primary focus of the article related to the adverse effect profile of medical marijuana. Medical marijuana efficacy studies were not assessed. In the absence of this information, case reports or reports of recreational marijuana use was used. Studies were excluded if published in languages other than English. Studies focusing on mechanisms of action, studies of pharmacodynamics or pharmacokinetic effects, unless these effects were due to drug-drug interactions were also excluded. We excluded articles that did not evaluate adverse events of medical marijuana as the primary purpose. Prescription products containing marijuana or derivatives were excluded from evaluation.
Results
A PubMed search revealed 58 articles with medical marijuana and adverse effect as a subheading. A total of 11 articles were identified with a MeSH search for medical marijuana and adverse effect. A total of 28 articles were reviewed that related to marijuana addiction, adverse reactions, drug interactions, and accidental exposures. Of the articles identified by PubMed and bibliographic searches, one was a meta-analysis, 17 were clinical studies, and 10 were case reports/series. 
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4 recreational marijuana two to three times weekly, with his last consumption being 2 hours prior to symptom onset.
29
In another report, a 26-year-old male with no cardiovascular disease risk factors other than smoking, was admitted to the emergency department following recreational cannabis and cigarette smoking three hours prior to symptom onset.
25
Yurtdas et al also summarized 13 published cases of marijuana-induced MI. Of these cases, most patients (n = 12/13) presented with chest pain and MI, and the time from cannabis consumption to symptom onset ranged from one hour to five days.
Since marijuana is also an analgesic, chronic users may not experience the same pain syndrome associated with myocardial infarctions and may delay getting medical assistance. 30 In addition, there have been case reports of cerebral ischemic events in recreational marijuana users.
31-34
All of this information is limited by few case reports and several methodological flaws. Furthermore, long-term effects of medical marijuana use have not been evaluated and the majority of adverse events were associated with recreational use.
35
Immune dysfunction / Cancer reports Gordan et al systematically reviewed the literature to determine medical adverse effects/consequences associated with marijuana for recreational use.
Since marijuana has been associated with immune dysfunction, marijuana use may increase the risk of a variety of infectious diseases. Recreational marijuana use has been associated with outbreaks in tuberculosis (TB), Neisseria meningitidis, and sexually transmitted diseases. [36] [37] [38] [39] [40] There may also be a risk for marijuana users to develop severe steatosis (fatty degeneration) and fibrosis in the liver. This effect was observed in patients with chronic hepatitis C who had a liver biopsy and were daily marijuana users. 41 Marijuana use has also been associated with an increased risk of cancer; however, studies evaluating the potential carcinogenic activity of marijuana had several methodological flaws that limit the interpretation of the literature. There may be an increased risk of bladder cancer, head/neck, and lung cancer in habitual marijuana smokers. [42] [43] [44] Respiratory Disorders Cannabis smoke contains many of the same carcinogens found in cigarette smoke; however, the effects of cannabis smoking on the respiratory system remain unclear. Marijuana smokers may have an increased risk of respiratory dysfunction (e.g., chronic bronchitis, increased mucus production, wheezing, increased hyperinflation, Forced Vital Capacity [FVC] , and residual volume in respiratory function tests). [45] [46] [47] [48] Inhaled marijuana may increase the risk of lung cancer, emphysema, bronchitis, reduced lung density, wheeze, phlegm, and cough. 15, 49 Studies over the past two decades have shown that regular recreational marijuana smokers report more chronic bronchitis than non-smokers and also have higher rates of respiratory infections and pneumonia. 15, 18 In a study assessing cannabis-related adverse events leading to hospitalization, respiratory system disorders were observed among 31.0% of patients (n=62/200) and consisted of dyspnea (n=16), hemoptysis (n=10), and spontaneous pneumothorax (n=7). The corresponding incidence was 1.6 per 1000 (95% CI 1.2, 2.0) among recent cannabis users. 24 Respiratory disorders associated with cannabis may be exacerbated in patients with underlying asthma and chronic obstructive pulmonary disease (COPD). 49 Cannabis smokers inhale more deeply than tobacco smokers, hold their smoke longer, and thereby retain more carcinogens, tar and particulate matter. Chronic cannabis smokers show pathological changes in lung cells that precede the development of cancer. 15 There is conflicting evidence as to whether smoking marijuana causes lung and other types of cancers, suggesting the need for further study in this area.
Marijuana has also been identified as a risk factor for developing bullous disease and pneumothorax. The incidence of bullae was higher in marijuana smokers in a retrospective evaluation of habitual marijuana smokers referred for treatment of spontaneous pneumothorax. Incidence of bullae was higher in marijuana smokers compared to non-marijuana smokers (7/10 vs. 3/10 patients, respectively, p<0.05). In another retrospective case series of 17 patients less than 40 years of age presenting with spontaneous pneumothoraxes, 16 patients reported smoking marijuana daily for a mean of 8.8 years and tobacco for 11.8 years. These findings have led to the terms "marijuana lung" and "bong lung" to describe patients developing large peripheral paraseptal lung bullae. 49 There is conflicting information regarding the adverse effects of medical marijuana on respiratory disorders (specifically cancers); however, asthma and COPD symptoms may be exacerbated with inhaled medical marijuana. Patients were excluded if they had problematic alcohol use (more than two drinks on one occasion), those with any drug use (other than marijuana) within 30 days of admission, and those who entered treatment on transfer from an inpatient or residential program that restricted their access to alcohol and drugs. A total of 12,770 patients met the inclusion criteria and were classified into the following groups: no marijuana use ("never users", n=11,344), those reporting marijuana use at admission, but not at four months after discharge ("stoppers", n=299), those reporting use at admission and four months after discharge ("continuing users", n=296), and those reporting no use at admission but reporting use four months after discharge (starters, n=831). A total of 850 subjects were randomly selected from the never-user group, yielding a total sample of 2,276 veterans.
Patients were evaluated at four months to assess PTSD symptom severity, employment status, violent behavior and composite measures of alcohol and drug use from the Addiction Severity Index (ASI). Marijuana use after treatment was associated with higher PTSD symptoms, more violent behavior, and alcohol use. 21 Pierre et al reports psychosis associated with cannabis use in a 24-year-old man who was hospitalized for insomnia, irritability and aggressiveness two years after military service. He was given quetiapine 100 mg/day and had a rapid resolution of symptoms. Six months later, the patient was rehospitalized with psychotic symptoms after converting to medical marijuana with an increased frequency of twice daily use. After a course of aripiprazole and substance abuse treatment, the patient discontinued cannabis use and remained psychotic free. 52 Greer et al evaluated PTSD symptoms collected during 80 psychiatric evaluations of patients applying to the New Mexico Medical Cannabis Program from 2009 to 2011. Results indicated that a greater than 75% reduction in symptoms, as measured by the Clinician Administered Posttraumatic Scale for DSM-IV (CAPS), was observed in patients using cannabis compared when they were not users of cannabis. 53 Increased psychotic symptoms in patients with PTSD receiving marijuana were identified by Bonn-Miller et al. 54 Patients (n=432, male) in the study participated in a residential PTSD treatment at Miscellaneous adverse drug reactions Several investigators have evaluated adverse drug reactions associated with medical marijuana. Wang et al evaluated the adverse effects associated with medical cannabinoid use (oral ∆-9-tetrahydrocannabinol or ∆-9 tetrahydrocannabinolcannabidiol and oromucosal ∆-9-tetrahydrocannabinolcannabidiol were evaluated) in a systematic review and meta analysis. 57 No studies involving the smoking of marijuana were included. A total of 31 studies (n = 1932 patients) was reviewed. In these studies, the median duration of cannabis exposure was two weeks (range, 8 hours to 12 months) and patients received cannabis for chronic conditions (e.g., cancer, multiple sclerosis). A total of 164 serious adverse events occurred in patients taking cannabinoid therapy compared to 60 among the control group (either placebo or standard care). The most common adverse events were relapse of multiple sclerosis, vomiting, and urinary tract infection. Among the randomized controlled studies, no statistically significant differences between serious adverse events were observed between groups (RR, 1.04; 95% CI, 0.78 -1.39). Adverse events were reported as respiratory (16.5%), gastrointestinal disorders (16.5%), nervous system disorders (15.2%), general disorders and administration-site conditions (12.85%), renal/urinary disorders (9.8%); neoplasm (benign and malignant) (8.5%), and psychiatric disorders (6.7%) The incidence for nonserious adverse events was significantly higher in patients taking cannabinoids than among patients assigned to the control group; (RR, 1.86; 95% CI, 1.57-2.21; P<0.001). Central nervous system (23.1%) and psychiatric disorders (10.3%) were the most common serious adverse events reported in the observational studies with no control group. However, this study was limited because it did not include reports of adverse events due to inhaled cannabis and only short-term use was evaluated (up to 12 months). 57, 58 Drug Interactions The major active ingredient in marijuana is delta-9-tetrahydrocannabinol (THC). This agent exerts its effects by binding to cannabinoid receptors that are present mainly in the central nervous system (CNS). Binding of THC to these receptors causes several therapeutic and psychoactive effects. 59 Effects are also associated with modulatory effects in neurotransmitters (e.g., acetylcholine, norepinephrine, dopamine, serotonin, gamma aminobutyric acid, glutamate, and D-aspartate). [59] [60] [61] The metabolism of THC has not been completely elucidated. Several enzymes appear to play a role in metabolism including CYP2C9 and CYP3A4. As a result, medications that are metabolized by either of these pathways are subjected to an increased risk of interactions. 62 There is a paucity of information related to drug-drug interactions with marijuana. Several interactions exist between dronabinol (marinol) and commercially available agents. In addition, major interactions exist between dronabinol and cocaine, ethanol, and droperidol. Other interactions include anxiolytics, barbiturates, disulfiram, monoamine oxidase inhibitors (MAOIs), protease inhibitors, selective serotonin reuptake inhibitors (SSRIs), sildenafil, sedatives, theophylline, tricyclic antidepressants, and warfarin. 59, 63 Most of the interactions cited in drug interaction monographs are theoretical in nature based on the proposed mechanism of action of dronabinol and the potential offending agent; however, case reports/clinical studies indicating a potential interaction have occurred with anticholinergics, barbiturates, disulfiram, lithium, protease inhibitors (e.g., indinavir, nelfinavir), SSRIs (e.g., fluoxetine), sildenafil, theophylline, tricyclic antidepressants, opioid analgesics, and warfarin. Crime / Car Accident Fatalities Medical marijuana dispensaries are perceived to be associated with increased criminal activity in proximity to dispensary location; however, few investigators have evaluated whether or not the dispensaries are associated with increased criminal activity. Although medical marijuana dispensaries produce conditions associated with an increased crime rate (e.g., burglary, robbery, assault, etc), the typical patient population (e.g., older White men) is not believed to be a high risk population for perpetrating crimes. 69 Kepple et al evaluated the crime rates associated with medical marijuana dispensaries in Sacramento, CA in an ecological, cross-section study. Results indicated that violent crime rates were not significantly related to the presence of a medical marijuana dispensary. However, a significant increase in crime rates were observed when there was a high population of individuals in the community between the ages of 15-24 years, high percentage of one-person households, high unemployment rate and high percentage of commercial zoning locations. 69 In another study, ease of access to medical marijuana was not a significant risk factor for fatal car crashes.
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Pharmacists' consideration Pharmacists may be asked to provide counseling to patients who are using medical marijuana. As a result, pharmacists need to know potential adverse effects, drug-drug interactions, and policies / procedures associated with dispensing medical marijuana. Several states have proposed that pharmacists be responsible for dispensing medical marijuana and although state laws may sanction this activity, federal laws will be violated. 71 In most states, pharmacists
are not allowed to recommend a source or provide instructions on how to obtain medical marijuana. Furthermore, Pharmacy and Therapeutics committees may be asked for guidance and or policy considerations regarding the dispensing of medical marijuana. 72, 73 The American Society of Health System Pharmacists (ASHP) "oppose(s) state legislation that authorizes the use of medical marijuana until there is sufficient evidence to support its safety and effectiveness and a standardized product that would be subject to the same regulations as a prescription drug product." ASHP encourages research into the effectiveness, safety and clinical use of medical marijuana and will advocate for development processes that would ensure standardization of the products. In addition to encouraging the DEA to eliminate barriers to medical research of medical marijuana (e.g., potentially reclassifying the product to something other than a Schedule 1 controlled substance), they oppose storage, procurement, and distribution of the product by licensed pharmacies/health facilities for uses other than research. 74 Clinical questions are still unanswered related to the use of medical marijuana including which method of delivery is best to product therapeutic effect without producing untoward adverse effects. The most efficacious method of delivery has not been established. In addition, the content of THC in cannabis may vary according to geographic origin, the part of the plant used, methods for storage, and cultivation techniques. 77 Cultivation can also be associated with contaminants in the cannabis. Biological contaminants of cannabis plants include fungus and bacteria.
At least two states with legalized medical marijuana prohibit the use of smoked marijuana. 5 In addition, the appropriate dosage of medical marijuana needs to be determined. If dispensed, pharmacists need to be able to ensure the potency of the products and ensure that the products are not contaminated with harmful substances.
Conclusion
The legalization of marijuana has led to the misconception that it is a safe, natural product with few side effects and no serious drug or disease state interactions. 21 Although a limited amount of information was located for medical marijuana, this information is based on the assumption that medical and recreational marijuana adverse effects are similar. The efficacy of medical marijuana in several disease states has not been elucidated; however, use may be associated with significant drug-drug interactions and adverse drug reactions. In addition, legalization has been associated with increased marijuana abuse/dependence and accidental exposures in children. Increased case reports of cardiovascular events following recreational marijuana use, its potential to exacerbate respiratory disorders, and the potential for psychiatric changes establishes the need for extensive study and education to minimize these events. In order to appropriately counsel patients, pharmacists need to be informed about the use of marijuana. Additional training is necessary and essential for pharmacists to understand and recognize the potential interactions with chronic medications, especially those used for marijuana approved disease states. Extensive investigation is needed to fully understand the pharmacologic effects of marijuana for treating disease states and to minimize the detrimental effects experienced by chronic users. Pharmacists play a key role in medication management, and the legalization of medical marijuana complicates this role with little guidance. Additional studies need to be performed to determine long-term adverse effects of medical marijuana in various populations. 
